CARMOXIROLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H26N2O2
Molecular Weight	374.4754
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC2=C(NC=C2CCCCN3CCC(=CC3)C4=CC=CC=C4)C=C1

InChI

InChIKey=AFSOIHMEOKEZJF-UHFFFAOYSA-N

InChI=1S/C24H26N2O2/c27-24(28)20-9-10-23-22(16-20)21(17-25-23)8-4-5-13-26-14-11-19(12-15-26)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,25H,4-5,8,12-15H2,(H,27,28)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9825185 | https://www.ncbi.nlm.nih.gov/pubmed/1682817

Carmoxirole is a dopamine D2 receptor agonist with limited central activity that modulates sympathetic activation and subsequently reduces pre-load and afterload in animals. It was shown, that carmoxirole induced beneficial effects on hemodynamic and neurohumoral parameters in heart failure. In addition, experimental evidence showed that carmoxirole lowered blood pressure in various models of hypertension mainly or exclusively through inhibition of noradrenaline release from sympathetic nerve endings. That effect of carmoxirole was mediated by presynaptic dopamine receptors with the characteristic that release inhibition was restricted to low rates of sympathetic nerve discharge.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
D(2) dopamine receptor 58 Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1682817	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart failure 103 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9825185	Primary		Not Provided 504	Unknown Approved Use Unknown
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1356783	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.	2002 Jun 28	12106810

Patents

Sample Use Guides

In Vivo Use Guide

Carmoxirole (0.25-1.00 mg) was administered on 2 consecutive days, and hemodynamic and neurohormonal measurements were carried out.

Route of Administration: Oral

In Vitro Use Guide

10 microM carmoxirole inhibited the adrenaline induced aggregation velocity by 10%: Increasing the carmoxirole concentration caused dose dependent inhibition which was complete at 1 mM. Carmoxirole itself caused a weak aggregating effect on human platelets in vitro.

Name

Type

Language

CARMOXIROLE

Official Name

English

CARMOXIROLE [MI]

Common Name

English

3-(4-(3,6-DIHYDRO-4-PHENYL-1(2H)-PYRIDYL)BUTYL)INDOLE-5-CARBOXYLIC ACID

Systematic Name

English

carmoxirole [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884